Zai Lab Limited

    Jurisdiction
    China
    LEI
    549300P2UYQ9U5LY1T58
    ISIN
    US98887Q1040 (ZLAB)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    52 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Read full profile

    Fundamentals

    Net revenue
    €364.89M
    Gross margin
    62.4%
    EBIT
    -€210.64M
    EBIT margin
    -57.7%
    Net income
    -€181.27M
    Net margin
    -49.7%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €710.34M +94.7% €25.99M -114.3%
    €1.05B +47.1% €161.65M +522.0%
    €1.58B +51.2% €373.00M +130.7%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 85K $3.05M -103K Sell

    Earnings Calls

    Latest earnings call: August 7, 2025 (Q2 2025)

    Add to watchlist

    Notifications